van Krieken J H J M, Langerak A W, Macintyre E A, Kneba M, Hodges E, Sanz R Garcia, Morgan G J, Parreira A, Molina T J, Cabeçadas J, Gaulard P, Jasani B, Garcia J F, Ott M, Hannsmann M L, Berger F, Hummel M, Davi F, Brüggemann M, Lavender F L, Schuuring E, Evans P A S, White H, Salles G, Groenen P J T A, Gameiro P, Pott Ch, Dongen J J M van
Department of Pathology, UMC St Radboud, Nijmegen, The Netherlands.
Leukemia. 2007 Feb;21(2):201-6. doi: 10.1038/sj.leu.2404467. Epub 2006 Dec 14.
The diagnosis of malignant lymphoma is a recognized difficult area in histopathology. Therefore, detection of clonality in a suspected lymphoproliferation is a valuable diagnostic criterion. We have developed primer sets for the detection of rearrangements in the B- and T-cell receptor genes as reliable tools for clonality assessment in lymphoproliferations suspected for lymphoma. In this issue of Leukemia, the participants of the BIOMED-2 Concerted Action CT98-3936 report on the validation of the newly developed clonality assays in various disease entities. Clonality was detected in 99% of all B-cell malignancies and in 94% of all T-cell malignancies, whereas the great majority of reactive lesions showed polyclonality. The combined BIOMED-2 results are summarized in a guideline, which can now be implemented in routine lymphoma diagnostics. The use of this standardized approach in patients with a suspect lymphoproliferation will result in improved diagnosis of malignant lymphoma.
恶性淋巴瘤的诊断在组织病理学领域是公认的难题。因此,在疑似淋巴细胞增殖性疾病中检测克隆性是一项有价值的诊断标准。我们已开发出用于检测B细胞和T细胞受体基因重排的引物组,作为疑似淋巴瘤的淋巴细胞增殖性疾病克隆性评估的可靠工具。在本期《白血病》杂志中,BIOMED - 2协同行动CT98 - 3936的参与者报告了新开发的克隆性检测方法在各种疾病实体中的验证情况。在所有B细胞恶性肿瘤中99%检测到克隆性,在所有T细胞恶性肿瘤中94%检测到克隆性,而绝大多数反应性病变显示为多克隆性。BIOMED - 2的综合结果总结在一份指南中,该指南现在可应用于淋巴瘤的常规诊断。在疑似淋巴细胞增殖性疾病患者中使用这种标准化方法将改善恶性淋巴瘤的诊断。